ACE Inhibitors vs ARBs: Efficacy and Side Effect Profile Comparison

Efficacy Comparison

• The American College of Cardiology recommends ACE inhibitors as first-line therapy for heart failure with reduced ejection fraction, post-myocardial infarction patients, and patients with diabetic nephropathy 1, 2, 3, 4, 5, 6
• ACE inhibitors have similar effects on symptoms and survival in heart failure with reduced ejection fraction (HFrEF) 1, 3
• ARBs produce similar hemodynamic, neurohormonal, and clinical effects to ACE inhibitors 1, 7
• The American College of Cardiology suggests that ARBs are recommended as alternatives when ACE inhibitors are not tolerated 1, 2, 7

Side Effect Profile Comparison

• ACE inhibitors have common side effects including cough (up to 20% of patients) and angioedema (less than 1% of patients) 1, 3
• ARBs have a more favorable side effect profile compared to ACE inhibitors, with a significantly lower incidence of cough and angioedema 1, 7

Clinical Decision Algorithm

• The American College of Cardiology recommends starting with an ACE inhibitor for initial therapy in most cardiovascular conditions, and switching to an ARB if the patient develops a persistent dry cough or angioedema 1, 2, 9
• Consider ARB as initial therapy when the patient has a history of ACE inhibitor-induced cough or angioedema, or is at higher risk for ACE inhibitor side effects 6, 7, 9

Important Clinical Pearls

• ARBs should not be initiated within 36 hours of discontinuing an ACE inhibitor due to the risk of overlapping effects 2
• Combination therapy with both ACE inhibitor and ARB is generally not recommended due to increased adverse effects without significant additional benefit 5
• Monitor renal function, potassium, and blood pressure closely when initiating either class of medication 1, 3